Minireview: Animal models and mechanisms of ovarian cancer development

Endocrinology

Volumn 153, Issue 4, 2012, Pages 1585-1592

  Mullany, Lisa K ^a   Richards, JoAnne S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; BETA CATENIN; K RAS PROTEIN; MUELLERIAN INHIBITING FACTOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; WNT PROTEIN;

CARCINOGENESIS; CELL CYCLE ARREST; COPY NUMBER VARIATION; EPITHELIUM CELL; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENOMIC INSTABILITY; GRANULOSA CELL; HEN; HUMAN; NONHUMAN; ONCOGENE C MYC; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; SIMIAN VIRUS 40; STROMA CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GRANULOSA CELL TUMOR; MICE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84859415438     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-2121     Document Type: Short Survey

References (63)

1. American Cancer Society 2009 What are the key statistics about ovarian cancer? Available at http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ ovarian-cancer-key-statistics
2. Romero IN, Bast Jr RC 2012 Human ovarian cancer: biology, current management and paths to personalizing therapy. Endocrinology 153:1593-1602
3. Bast RC, Hennessy B, Mills GB 2009 The biology of ovarian cancer: new opportunities for translation. Nature Rev Cancer 9:415-428
4. Cho KR, Shih I-M 2009 Ovarian cancer. Ann Rev Path 4:287-313
5. Auersperg N 2011 The origin of ovarian carcinomas: a unifying hypothesis. In J Gynecol Pathol 30:12-21
6. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC 2001 Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev 22:255-288 (Pubitemid 32458162)
7. Cancer Genome Atlas Research Network 2011 Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615
8. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM 2010 BRAF mutation is rare in advanced stage low-grade ovarian serous carcinomas. Am J Pathol 177:1611-1617
9. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ 2005 Expression profiling of serous low grade malignant potential, low-grade, and high grade tumors of the ovary. Cancer Res 65:10602-10612 (Pubitemid 41743756)
10. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL 2009 Histopathology of ovarian tumors in laying hens, a preclinical model of human ovarian cancer. Int J Gynecol Cancer 19:531-539
11. Treviño LS, Giles JR, Wang W, Urick ME, Johnson PA 2010 Gene expression profiling reveals differentially expressed genes in ovarian cancer in the hen: support for oviductal origin? Horm Cancer 1:177-186
12. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC 2005 Models of ovarian cancer - are we there yet? Mol Cell Endocrinol 239:15-26 (Pubitemid 40848725)
13. King SM, Burdette JE 2011 Evaluating the progenitor cells of ovarian cancer: analysis of current mouse models. BMB Rep 44:435-445
14. Cheon D-J, Orsulic S 2011 Mouse models of cancer. Ann Rev Pathol Mech Dis 6:95-119
15. Vanderhyden BC, Shaw TJ, Ethier JF 2003 Animal models of ovarian cancer. Reprod Biol Endocrinol 1:67-76
16. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE 2002 Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62 (Pubitemid 41039176)
17. Xing D, Orsulic S 2005 A genetically defined mouse ovarian carcinoma model for molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci USA 102:6936-6941 (Pubitemid 40675420)
18. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY 2003 Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63:3459-3463 (Pubitemid 36793020)
19. Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Körner S, Wang W, Boccaccio C, Thorgeirsson SS, Comoglio PM, Hermeking H, Nikitin AY 2011 Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 108:14240-14245
20. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC 2003 Female mice chimeric for expression of the Simian virus 40T Ag under the control of the MISRIIR promoter develop epithelial ovarian cancer. Cancer Res 63:1389-1397 (Pubitemid 36348722)
21. Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, Connolly DC 2010 Development of a syngenic mouse model of epithelial ovarian cancer. J Ovarian Res 3:24-41
22. Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, Handlogten MW, Alves NJ, Bilgicer B, Dinulescu DM, Mashelkar RA, Sengupta S 2010 Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci USA 107:12435-12440
23. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP 2007 A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211:26-35 (Pubitemid 46092026)
24. Miyoshi I, Takahashi K, Kon Y, Okamura T, Mototani Y, Araki Y, Kasai N 2002 Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T antigen: tumor formation and its hormonal regulation. Mol Reprod Devel 63:168-176 (Pubitemid 34971376)
25. Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC 2009 Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 4:e8534
26. Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC 2009 Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 4:e8404
27. Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S 2009 A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 69:8231-8235
28. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T 2005 Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63-70 (Pubitemid 40215839)
29. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR 2007 Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/b-catenin and PI3K/Ptten pathways. Cancer Cell 11:321-333 (Pubitemid 46518315)
30. Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ, Richards JS 2009 Cell type specific targeted mutation of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult in ovarian surface epithelial cells. Cancer Res 69:6463-6472
31. Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong KK, Richards JS 2011 Molecular characterization of ovarian surface epithelial cells transformed by oncogenes. Oncogene 30:3522-3536
32. Mullany LK, Liu Z, King E, Wong KK, Richards JS 2012 Wild type tumor repressor protein 53 (TRP53) promotes ovarian cancer survival. Endocrinology 153:1638-1648
33. G12D in granulosa cells of the mouse ovary causes defects in follicular development and ovulation. Development 135:2127-2137
34. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintás-Cardama A, Bankson JA, El-Naggar AK, Lozano G 2011 Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121:893-904
35. Jackson JG, Post SM, Lozano G 2011 Regulation of tissue- and stimulus- specific cell fate decisions by p53 in vivo. J Pathol 223:127-136
36. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA 2007 Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447:966-971 (Pubitemid 46975753)
37. Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, Alt FW, DePinho RA 2003 Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 421:643-648 (Pubitemid 36227673)
38. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T 2010 Stage-specific sensitivity to p53 restoration during lung cance progression. Nature 468:572-575
39. Young NP, Crowley D, Jacks T 2011 Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 71:4040-4047
40. Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast Jr RC, Mills GB, Silva EG 1999 Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5:4053-4058 (Pubitemid 30013784)
41. Ahmed AA, Etemadmoghadam E, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD 2010 Driver mutations in TP53 are ubiquitous in high grade serous adenocarcinomas of the ovary. J Pathol 22:49-56
42. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE 2007 Identification of an integrated SV40T/t-antigen cancer signature in aggressive human breast, prostate and lung carcinomas with poor prognosis. Cancer Res 67:8065-8080 (Pubitemid 47395141)
43. Salehi F, Dunfield L, Philips KP, Krowski D, Vanderhyden BC 2008 Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health 11:301-321 (Pubitemid 351451267)
44. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC 2002 Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer I 94:32-38 (Pubitemid 34082841)
45. Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB 2010 Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res 70:8927-8936
46. Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, Vanderhyden BC 2010 17b-Estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology 151:929-938
47. Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y 2008 Progesterone facilitates cisplatin toxicity in epithelial ovarian cance cells and xenografts. Gynecol Oncol 110:251-255
48. Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E 2009 Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice. Cancer Prev Res 2:792-799
49. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG 2009 Mutation of FOXL2 in granulosa cell tumors for the ovary. N Engl J Med 360:2719-2729
50. Jamieson S, Butzow R, andersson N, alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ, Anttonen M 2010 The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Modern Pathol 23:1477-1485
51. Fleming NI, Knower KC, Lazarus KA, Fuller PJ, Simpson ER, Clyne CD 2010 Aromatase is a direct target of FOXL2:C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter. PLoS One 5:e14389
52. Middlebrook BS, Eldin K, Li X, Shivasankaran S, Pangas SA 2009 Smad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cells tumors. Endocrinology 150:5208-5217
53. Pangas SA 7 July 2011 Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells. Mol Cell Endocrinol 10.1016/j.mce.2011.06.021
54. Edson MA, Nalam RL, Clementi C, Franco HL, Demayo FJ, Lyons KM, Pangas SA, Matzuk MM 2010 Granulosa cell-expresed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol 24:1251-1266
55. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A 1992 a-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313-319 (Pubitemid 23000668)
56. Fan X, Gabbi C, Kim HJ, Cheng G, Andersson LC, Warner M, Gustafsson JA 2010 Gonadotropin-positive pituitary tumors accompanied by ovarian tumors in aging female ERb-/- mice. Proc Natl Acad Sci USA 107:6453-6458 1
57. Alexiadis M, Eriksson N, Jamieson S, Davis M, Drummond AE, Chu S, Clyne CD, Muscat GE, Fuller PJ 2011 Nuclear receptor profiling of ovarian granulosa cell tumors. Horm Cancer 2:157-169
58. Boerboom D, Paquet M, Hsieh M, Liu J, Jamin SP, Behringer RR, Sirois J, Taketo MM, Richards JS 2005 Misregulated Wnt/b-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res 65:9206-9215 (Pubitemid 41507986)
59. Fan HY, Liu Z, Cahill N, Richards JS 2008 Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 22:2128-2140
60. Laguë MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A, Doré M, Huneault LM, Richards JS, Boerboom D 2008 Synergistic effects of Pten loss and WNT/CTNNB1 signaling pathway activation in granulosa cell tumor development and progression. Carcinogenesis 29:2062-2072
61. Boyer A, Paquet M, Laguë MN, Hermo L, Boerboom D 2009 Dysregulation of WNT/CTNNB1 and PI3K/AKT signaling in testicular stromal cells causes granulosa cell tumors of the testis. Carcinogenesis 30:869-878
62. Richards JS, Fan HY, Liu Z, Tsoi M, Lague MN, Boyer A, Boerboom D 22 August 2011 Either Kras activation or Pten loss similarly enhances the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis. Oncogene 10.1038/onc.2011.1341
63. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk M.M. 2012 High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci 10.1073/pnas.1117135109